Walleye Capital
RNAM

Walleye Capital’s Avidity Biosciences RNAM Stock Holding History

Walleye Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-91,935
Closed -$2.67M – 5005
2024
Q4 		$2.67M Buy
+91,935
New +$3.84M 0.01% 1511
2023
Q4 		– Sell
-123,220
Closed -$786K – 5429
2023
Q3 		$786K Buy
123,220
+110,885
+899% +$955K ﹤0.01% 2452
2023
Q2 		$137K Buy
+12,335
New +$155K ﹤0.01% 3300
2022
Q4 		– Sell
-270,907
Closed -$4.42M – 3562
2022
Q3 		$4.42M Sell
270,907
-1,399
-0.5% -$26.8K 0.08% 256
2022
Q2 		$3.96M Buy
272,306
+132,671
+95% +$1.97M 0.11% 206
2022
Q1 		$2.58M Buy
+139,635
New +$2.37M 0.07% 298

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's RNAM Position: Q1 2025 in Review

Walleye Capital sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 91,935 shares — an estimated $2.67M sold.

Walleye Capital first reported a position in RNAM in Q1 2022 and held it in 6 quarters. The position peaked at $4.42M in Q3 2022. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Walleye Capital reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 91,935 Avidity Biosciences shares in Q1 2025, an estimated $2.67M.
  • Walleye Capital first reported a position in Avidity Biosciences in Q1 2022 and held it in 6 quarters.
  • Walleye Capital's Avidity Biosciences position peaked at $4.42M in Q3 2022.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.